# TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. v. AMNEAL PHARMACEUTICALS OF NEW YORK, LLC

> District Court, D. New Jersey · June 10, 2024

URL: https://www.frixlaw.com/law-library/cases/10278859

## Case

- **Court:** District Court, D. New Jersey
- **Decided:** June 10, 2024
- **Opinion:** 100trialcourt
- **Cited by:** 0 later opinions in the Frix Law Library

## Citator (automated)

- No negative treatment found by the automated citator. That is not the same as a confirmation that the case is good law; read the citing cases.
- Full citator and citing cases: https://www.frixlaw.com/law-library/cases/10278859

## Opinion text

FOR PUBLICATION

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY
_______________________________________
:
TEVA BRANDED PHARMACEUTICAL :
PRODUCTS R&D, INC., NORTON :
(WATERFORD) LTD., AND TEVA :
PHARMACEUTICALS USA, INC., : Civil Action No. 23-20964 (SRC)
:
:
: OPINION & ORDER
Plaintiffs, :
:
v. :
:
AMNEAL PHARMACEUTICALS OF :
NEW YORK, LLC, AMNEAL IRELAND :
LIMITED, AMNEAL PHARMACEUTICALS :
LLC, AND AMNEAL :
PHARMACEUTICALS INC. :
:
Defendants. :
_______________________________________:

CHESLER, U.S.D.J.
This matter comes before the Court on two motions: 1) the motion to dismiss by
Plaintiffs Teva Branded Pharmaceutical Products R&D, Inc., Norton (Waterford) Ltd., and Teva
Pharmaceuticals USA, Inc. (collectively, “Teva”); and 2) the motion for partial judgment on the
pleadings, pursuant to Federal Rule of Civil Procedure 12(c), by Defendants Amneal
Pharmaceuticals Of New York, LLC, Amneal Ireland Limited, Amneal Pharmaceuticals LLC,
and Amneal Pharmaceuticals Inc. (collectively, “Amneal.”) For the reasons that follow, the
motion to dismiss will be denied, and the motion for partial judgment on the pleadings will be
granted.

1
This case arises out of a patent infringement dispute under the Hatch-Waxman Act
between Teva and Amneal. Teva holds approved NDA No. 021457 for ProAir® HFA
(albuterol sulfate) Inhalation Aerosol (“ProAir® HFA”), and owns certain patents listed in the
Orange Book as covering this product: U.S. Patent Nos. 8,132,712 (the “’712 patent”), 9,463,289
(the “’289 patent”), 9,808,587 (the “’587 patent”), 10,561,808 (the “’808 patent”), and

11,395,889 (the “’889 patent”) (collectively, the “Patents at issue” or the “Inhaler Patents”).
Amneal has filed ANDA No. 211600, seeking to make and sell a generic version of ProAir®
HFA. The following facts are undisputed. The Amneal ANDA contains a paragraph IV
certification that the proposed product will not infringe any valid claim of the Patents at issue.
After Amneal sent Teva the required notice letter, Teva filed the instant suit. The Amended
Complaint asserts claims for patent infringement of the Patents at issue. Amneal filed an
Amended Answer to the Amended Complaint asserting, inter alia, twelve counterclaim counts.
Counterclaim Counts 1-5 seek declarations ordering Teva to delist the Patents at issue from the
Orange Book. Counterclaim Counts 6-9 allege violations of the Sherman Act, and Count 10

alleges a violation of the New Jersey Antitrust Act, N.J.S.A. § 56:9. Counterclaims 11 and 12
are not at issue on these motions.
The Federal Trade Commission (“FTC”) requested and was granted leave to file a brief
as amicus curiae.
I. Teva’s motion to dismiss Counterclaim Counts 6-10
Teva moves to dismiss Counterclaim Counts 1-10. The Court first considers the motion
to dismiss the antitrust counterclaims, Counterclaim Counts 6-10. Teva contends that the

2
antitrust counterclaims are premised on two forms of alleged anticompetitive conduct: 1)
improper Orange Book listing; and 2) sham litigation.
Teva contends that antitrust law provides no cause of action for improper Orange Book
listing. First, Teva argues that because “Teva’s patents are properly listed as a matter of law . . .
any claim based on purported improper listing necessarily fails.” (Pls.’ MTD Br. at 25.) Later

in this Opinion, this Court will consider and address Amneal’s motion for judgment on the
pleadings; as will be explained, the Court concludes that Teva’s patents are not properly listed in
the Orange Book as a matter of law. This conclusion does not support a Rule 12(b)(6)
dismissal of an antitrust claim for improper Orange Book listing.
Second, Teva argues that, even if the Court were to find that the listings are improper,
given the Trinko doctrine, “antitrust law does not create a cognizable claim for Amneal based on
purported improper listing in any event.” (Pls.’ MTD Br. at 25.) In short, Teva argues that the
instant case is analogous to Trinko, but this Court is not persuaded. The Supreme Court’s
syllabus for Trinko states the relevant key points of that case:

The Telecommunications Act of 1996 imposes upon an incumbent local exchange
carrier (LEC) the obligation to share its telephone network with competitors.
. . .
Held: Respondent's complaint alleging breach of an incumbent LEC’s 1996 Act
duty to share its network with competitors does not state a claim under § 2 of the
Sherman Act.
. . .
(c) Traditional antitrust principles do not justify adding the present case to the few
existing exceptions from the proposition that there is no duty to aid competitors.

Verizon Communs., Inc. v. Law Offices of Curtis V. Trinko, LLP, 540 U.S. 398, 398-99
(2004). Teva argues that the Listing Statute, 21 U.S.C. § 355, imposes upon an NDA holder an
analogous obligation:

3
[T]he Hatch-Waxman Act created a statutory obligation on a brand drug company
to list patents in the Orange Book in order to help generic drug companies
compete with the brand company by getting FDA approval for and launching their
competing generic products more quickly. This duty is, for all relevant purposes,
indistinguishable from the statutory duty imposed on incumbent service providers
at issue in Trinko.

(Pls.’ MTD Opening Br. at 28.)
Teva has failed to persuade this Court that the statutes at issue in the two cases are
analogous. As the statement from the Supreme Court’s Syllabus makes clear, the key attribute
of the statutory provision at issue was that it “imposes . . . the obligation to share its telephone
network with competitors.” Trinko, 540 U.S. at 398. The Listing Statute does not impose any
analogous obligation on the holder of an NDA. In fact, the Listing Statute says nothing about
competitors or other drug companies; it speaks only about certain information that must be
submitted “to the Secretary as part of the application.” 21 U.S.C. § 355(b)(1)(A). That
subsection, 21 U.S.C. § 355(b)(1)(A), lists eight subparagraphs which set forth what must be
submitted to the Secretary as part of the application.
Teva offers nothing more than ipse dixit in support of its argument that the duty imposed
by the Listing Statute is “indistinguishable” from the statutory duty at issue in Trinko. Teva’s
opening brief quotes the Supreme Court’s discussion of the Hatch-Waxman Act in Caraco: “To
facilitate the approval of generic drugs as soon as patents allow, the Hatch-Waxman
Amendments and FDA regulations direct brand manufacturers to file information about their
patents.” Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S, 566 U.S. 399, 405 (2012). This
says nothing about anyone helping competitors or cooperating with competitors. Teva has
given this Court no basis to find that the Listing Statute imposes on NDA applicants a duty to aid
competitors.

4
Furthermore, the FTC aptly summarizes the bases for distinguishing Trinko from the
instant case as follows:
Trinko is inapplicable because Amneal’s counterclaims are not an expansion of
antitrust law, the FDA does not directly police the Orange Book, and the statutory
amendment to add a delisting counterclaim does not transform a patent
enforcement framework into an antitrust regulatory scheme.

(FTC Amicus Br. at 33.) The FTC contends that the FDA’s ministerial role1 in Orange Book
listings differs greatly from the extensive scheme for FCC regulation of telecommunications
competition described in Trinko. The Telecommunications Act of 1996 established the
regulatory scheme of interest in Trinko:
The Telecommunications Act of 1996, Pub. L. 104-104, 110 Stat. 56, imposes
certain duties upon incumbent local telephone companies in order to facilitate
market entry by competitors, and establishes a complex regime for monitoring
and enforcement. . .

The 1996 Act sought to uproot the incumbent LECs’ monopoly and to introduce
competition in its place. Central to the scheme of the Act is the incumbent
LEC’s obligation under 47 U.S.C. § 251(c) to share its network with competitors.

Trinko, 540 U.S. at 401-2 (citations omitted). Teva does not contend that, in enacting the
Orange Book listing provisions of the Hatch-Waxman Act, Congress sought to uproot any
monopolies, nor that, as to the Orange Book, the FDA has any enforcement function. The only
enforcement mechanism Teva points to is the delisting counterclaim – but this is plainly a
judicial remedy2 (as Teva admits), not an enforcement power entrusted to a regulator.

1 See Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC, 60 F.4th 1373, 1378 (Fed. Cir. 2023)
(“Notably, the FDA does not verify that submitted patents actually meet statutory listing criteria,
nor does the FDA proactively remove improperly listed patents. See Apotex, Inc. v. Thompson,
347 F.3d 1335, 1347 (Fed. Cir. 2003) (‘[T]he FDA's . . . duties with respect to Orange Book
listings are purely ministerial.’)”)
2 In Trinko, the Supreme Court expressed skepticism that, where continuing supervision is
needed, a court could serve as an effective enforcer. Id. at 415 (“An antitrust court is unlikely to

5
Compare this judicial remedy to the “regulatory structure” the Supreme Court described in
Trinko:
One factor of particular importance is the existence of a regulatory structure
designed to deter and remedy anticompetitive harm. Where such a structure
exists, the additional benefit to competition provided by antitrust enforcement will
tend to be small, and it will be less plausible that the antitrust laws contemplate
such additional scrutiny. Where, by contrast, there is nothing built into the
regulatory scheme which performs the antitrust function, the benefits of antitrust
are worth its sometimes considerable disadvantages. . . .

The regulatory framework that exists in this case demonstrates how, in certain
circumstances, regulation significantly diminishes the likelihood of major
antitrust harm.

Id. at 412 (citations omitted). Teva has not demonstrated that the Orange Book listing
provisions at issue comprise a regulatory structure designed to deter and remedy anticompetitive
harm. In the absence of such a regulatory structure, the Supreme Court stated, it is more
plausible that antitrust law provides additional scrutiny.
Having reviewed the enforcement mechanisms established by the Telecommunications
Act of 1996, the Supreme Court concluded that “the [regulatory] regime was an effective
steward of the antitrust function.” Id. at 413. In the instant case, Teva does not even claim
that there is any regulator with enforcement powers. This Court is not persuaded that
availability of the judicial remedy of delisting significantly diminishes the likelihood of major
antitrust harm, nor that this remedy alone is an effective steward of the antitrust function. As
the FTC points out, the judicial delisting remedy does not provide for damages; that remedy
alone cannot be an effective steward of the antitrust function.

be an effective day-to-day enforcer of these detailed sharing obligations.”)

6
In sum, amicus FTC has persuasively distinguished Trinko. Teva has failed to persuade
that Trinko is analogous and forecloses Amneal’s antitrust counterclaims.
Teva argues as well that the plain language of the Listing Statute precludes an antitrust
claim predicated on improper listing, citing 21 U.S.C. § 355(j)(5)(c)(ii)(II), which states:
(ii) Counterclaim to infringement action.

(I) In general. If an owner of the patent or the holder of the approved
application under subsection (b) for the drug that is claimed by the patent
or a use of which is claimed by the patent brings a patent infringement
action against the applicant, the applicant may assert a counterclaim
seeking an order requiring the holder to correct or delete the patent
information submitted by the holder under subsection (b) or (c) on the
ground that the patent does not claim either—
(aa) the drug for which the application was approved; or
(bb) an approved method of using the drug.

(II) No independent cause of action. Subclause (I) does not authorize the
assertion of a claim described in subclause (I) in any civil action or
proceeding other than a counterclaim described in subclause (I).

Again, Teva presents only an ipse dixit conclusion about the meaning of 21 U.S.C. §
355(j)(5)(c)(ii)(II), without analysis or argument. On its face, subclause (II) delimits the
authority of subclause (I), which authorizes the assertion of a counterclaim to correct Orange
Book information in particular cases. The clear purpose of subclause (II) is to bar an
independent suit seeking the relief stated in subsection (I) in the absence of a Hatch-Waxman
infringement suit; it is designed to prevent the filing of claims for correction of the Orange Book
as independent actions.
Amneal has asserted Counterclaim Counts 1-5, seeking orders of correction, and these
appear to be permitted by 21 U.S.C. § 355(j)(5)(c)(ii); Teva does not argue that Counts 1-5 are
not permitted by 21 U.S.C. § 355(j)(5)(c)(ii). Teva does not explain how 21 U.S.C. §

7
355(j)(5)(c)(ii) impacts the assertion of the Counterclaim Counts 6-10 under antitrust law.
Counts 6-10 do not seek any order requiring the holder to correct or delete Orange Book
information. Counts 6, 9, and 10 reference improper listing in the Orange Book as an example
of an anticompetitive act. (Am. Answer at ¶¶ 281, 318, 322.) Count 7 does not mention the
Orange Book. Count 8 references improper listing of patents in the Orange Book as an

example of “a predatory scheme to monopolize the Relevant Market.” (Am. Answer at ¶ 310.)
Counterclaim Counts 6-10 do not seek correction or deletion of information in the Orange Book
and do not fall within the ambit of 21 U.S.C. § 355(j)(5)(c)(ii)(I).
The Court finds that subsections (I) and (II) neither authorize nor prohibit Counterclaim
Counts 6-10. Teva has offered nothing to support its contention that the plain language of these
subsections prohibits the assertion of the antitrust counterclaims.
Teva next argues that Counterclaim Count 7, for sham litigation in violation of the
Sherman Act, fails to state a valid claim. Teva’s arguments for dismissal are all variants of the
contention that Count 7 is unlikely to succeed at trial or summary judgment. As the Supreme

Court stated in Twombly, “of course, a well-pleaded complaint may proceed even if it strikes a
savvy judge that actual proof of those facts is improbable, and ‘that a recovery is very remote
and unlikely.’” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 556 (2007) (quoting Scheuer v.
Rhodes, 416 U.S. 232, 236 (1974).) Teva does no more here than argue that recovery on Count
7 is remote and unlikely; Plaintiff does not argue that Count 7 fails to plead a legally cognizable
claim for relief.
Next, Teva argues that Count 6, alleging an anticompetitive scheme, fails to state a claim
because the counterclaim components of that scheme all fail to state valid claims. Because this

8
Court has concluded that Amneal has pled viable claims for anticompetitive conduct, it is not
persuaded that Count 6 is invalid because all the other counterclaims are also invalid.
The Court concludes that Teva has failed to persuade that any of the antitrust
counterclaims fail to state a legally cognizable claim for relief, and the Rule 12(b)(6) motion to
dismiss the antitrust counterclaims will be denied.

II. Counterclaim Counts 1-5 and the Listing Statute
As to the delisting counterclaims, Counts 1-5, Teva moves to dismiss them too. Amneal
cross-moves for judgment on the pleadings on Counterclaim Counts 1-5. The Third Circuit has
stated:
We analyze a motion for judgment on the pleadings under Federal Rule of Civil
Procedure Rule 12(c) under the same standards that apply to a Rule 12(b)(6)
motion. Under Rule 12(c), a court must accept all of the allegations in the
pleadings of the party against whom the motion is addressed as true and draw all
reasonable inferences in favor of the non-moving party. A court may grant a Rule
12(c) motion if, on the basis of the pleadings, the movant is entitled to judgment
as a matter of law. A plaintiff can survive a Rule 12(c) motion if her complaint
contains sufficient factual matter to show that the claim is facially plausible, thus
enabling the court to draw the reasonable inference that the defendant is liable for
[the] misconduct alleged.

Bibbs v. Trans Union LLC, 43 F.4th 331, 339 (3d Cir. 2022) (citations omitted.)
In short, Teva contends that the delisting claims are premised on erroneous
interpretations of the Listing Statute. As to Amneal’s motion for judgment on the pleadings,
Amneal and amicus the FTC argue that the listing of the Inhaler Patents in the Orange Book is
improper and not authorized by the Listing Statute. Both of these motions turn on issues of
interpretation of the Listing Statute.
The Listing Statute states, in relevant part:
(b) Filing application; contents.

9
(1)
(A) Any person may file with the Secretary an application with respect to
any drug subject to the provisions of subsection (a). Such persons shall
submit to the Secretary as part of the application—
. . .
(viii) the patent number and expiration date of each patent for which a
claim of patent infringement could reasonably be asserted if a person not
licensed by the owner of the patent engaged in the manufacture, use, or
sale of the drug, and that—
(I) claims the drug for which the applicant submitted the
application and is a drug substance (active ingredient) patent or a
drug product (formulation or composition) patent; or
(II) claims a method of using such drug for which approval is
sought or has been granted in the application.

21 U.S.C. § 355. Although the Orange Book is not mentioned by name in the statute, the
parties agree that 21 U.S.C. § 355(b)(1)(A)(viii) states the fundamental requirements to effect the
listing of a patent in the Orange Book. Subsection § 355(b)(1)(A)(viii) authorizes the listing of
certain patents of three kinds: drug substance patents, drug product patents, and method of use
patents. Teva contends that the Inhaler Patents are drug product patents, and that they are
properly listed pursuant to § 355(b)(1)(A)(viii)(I).
Subsection § 355(b)(1)(A)(viii)(I) states two requirements: 1) the patent must “claim[]
the drug for which the applicant submitted the application;” and 2) the patent must be directed to
a drug substance or a drug product. This Court finds that the listing issue in this case turns on
the interpretation of the first element and concludes, in short, that the Inhaler Patents do not
claim the drug for which the applicant submitted the application.
There is no dispute that the Inhaler Patents contain no claim for the active ingredient at
issue, albuterol sulfate. Amneal contends that the Inhaler Patents do not meet the requirement
that they claim the relevant drug. The FTC agrees.

10
Teva points out that the word “drug” in § 355 is expressly defined in 21 U.S.C. §
321(g)(1):
The term “drug” means (A) articles recognized in the official United States
Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or
official National Formulary, or any supplement to any of them; and (B) articles
intended for use in the diagnosis, cure, mitigation, treatment, or prevention of
disease in man or other animals; and (C) articles (other than food) intended to
affect the structure or any function of the body of man or other animals; and (D)
articles intended for use as a component of any article specified in clause (A), (B),
or (C).

The Court acknowledges that this definition includes articles intended for use in the treatment of
disease, and that the ProAir® HFA inhaler falls within its scope. The problem for Teva is that
this broad statutory definition of drug does not suffice to establish that the Inhaler Patents claim
the drug for which Teva submitted its application, NDA No. 021457.3 Teva offers the FDA
approval letter for this NDA, dated October 29, 2004; the first line of this letter states: “Please
refer to your new drug application (NDA) dated January 30, 2003, received January 31, 2003,
submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for
albuterol sulfate HFA Inhalation Aerosol.” (Answer Ex. A at 1.) According to the FDA, the
drug for which the applicant submitted the NDA is “albuterol sulfate HFA Inhalation Aerosol.”
Furthermore, the Amended Complaint states:
45. Teva Branded is the holder of New Drug Application (“NDA”) No. 021457,
under which FDA approved the commercial marketing of ProAir® HFA
(albuterol sulfate) Inhalation Aerosol on October 29, 2004. ProAir® HFA
(albuterol sulfate) Inhalation Aerosol is indicated for the treatment or prevention
of bronchospasm in patients 4 years of age and older with reversible obstructive

3 It is not sufficient that a patent claim a drug that falls within the scope of the definition of
“drug” in 21 U.S.C. § 321(g)(1); the statute requires that the patent claim the drug for which the
applicant submitted the application. Teva overlooks the significance of the statutory language
that modifies the phrase, “the drug.”

11
airway disease and for the prevention of exercise-induced bronchospasm in
patients 4 years of age and older.

46. On October 1, 2022, the manufacturing of branded ProAir® HFA (albuterol
sulfate) Inhalation Aerosol was discontinued. Teva USA currently distributes an
authorized generic of ProAir® HFA (albuterol sulfate) Inhalation Aerosol under
NDA No. 021457 in the United States.

Teva has thus premised this case on the factual allegation that the subject of NDA No. 021457
was the product, “ProAir® HFA (albuterol sulfate) Inhalation Aerosol.” It is undisputed that
no claim in any of the Inhaler Patents discloses albuterol sulfate.
The First Circuit construed the phrase, a patent which “claims the drug for which the
applicant submitted the application,” as used in § 355, in Cesar Castillo, Inc. v. Sanofi-Aventis
U.S., LLC (In re Lantus Direct Purchaser Antitrust Litig.), 950 F.3d 1, 3 (1st Cir. 2020). Teva
objects that, despite Lantus being a 2020 case, Congress has since changed the language of § 355
with the passage of the Orange Book Transparency Act (“OBTA”). Indeed, the OTBA did
make changes to the language of § 355, but the key phrase, “claims the drug for which the
applicant submitted the application,” has not changed. At the time the First Circuit decided
Lantus, the listing provision in § 355 required that the NDA applicant list a patent which “claims
the drug for which the applicant submitted the application,” and the current Listing Statute
contains the same requirement today. Congress may have amended parts of the Listing Statute,
but the OTBA did not change this particular requirement for listing a patent in the Orange Book:
a listed patent must still claim the drug for which the applicant submitted the application.
In Lantus, Sanofi a filed a supplemental NDA “to sell insulin glargine in a disposable
injector pen device called the Lantus SoloSTAR.” Lantus, 950 F.3d at 5. The patent at issue,
the ‘864 patent, was directed to drive mechanisms used in drug delivery devices. Id. In short,

12
the First Circuit found that the ‘864 patent did not claim the drug for which the applicant
submitted the application. Id. at 8. Moreover, the First Circuit rejected the idea that § 355
authorizes the listing of “patents that claim only components of a proposed drug.” Id. at 9.
The Court concluded:
More importantly, even assuming that the drive mechanism claimed by the ‘864
patent is itself a drug, we still find Sanofi falling short of its goal because the
drive mechanism is not the “drug for which [Sanofi] submitted” the NDA. 21
U.S.C. § 355(b)(1). For that reason alone the patent for the drive mechanism does
not qualify for listing in the Orange Book as claiming the Lantus SoloSTAR.
. . .
The statute and regulations clearly require that only patents that claim the drug for
which the NDA is submitted should be listed in the Orange Book. The ‘864
patent, which neither claims nor even mentions insulin glargine or the Lantus
SoloSTAR, does not fit the bill.

Id. at 9-10.
The facts of Lantus are parallel to those of the instant case. The Inhaler Patents are
directed to components of a metered inhaler device, but do not claim or even mention albuterol
sulfate or the ProAir® HFA. The applicant filed an NDA for an albuterol sulfate HFA
Inhalation Aerosol. The statutory requirement that each patent “claim[] the drug for which the
applicant submitted the application” is not met.
The FTC points out that the Second Circuit followed the relevant reasoning of Lantus in
United Food & Commer. Workers Local 1776 v. Takeda Pharm. Co., 11 F.4th 118, 134 (2d Cir.
2021). United is a meaty opinion and much could be said about it, but two points are most
relevant: 1) the Second Circuit decided United after passage of the OBTA and agreed with the
pre-OBTA Lantus decision about the interpretation of “claims the drug for which the applicant
submitted the application” in the Listing Statute; and 2) “claims” in the Listing Statute has the
meaning established in patent law: “patent claims ‘are the numbered paragraphs which

13
particularly point out and distinctly claim the subject matter which the applicant regards as his
invention” (United, 11 F.4th at 132 (quoting Corning Glass Works v. Sumitomo Elec. U.S.A.,
Inc., 868 F.2d 1251, 1258 (Fed. Cir. 1989)). Applying the Second Circuit’s analysis to the
instant case, because the Inhaler Patents plainly do not regard an “albuterol sulfate HFA
Inhalation Aerosol” as that which was invented, they do not claim the drug for which the

applicant submitted the NDA application.
Teva offers two strategies that attempt to expand the scope of the key phrase in § 355,
“claims the drug.” First, Teva proffers a confusing set of arguments about the meaning of the
word, “claims.” Teva begins with the uncontroversial proposition that the word “claims” in the
Listing Statute “should be given its meaning under patent law.” (Pls.’ MJP Opp. Br. at 13.)
Somehow, Teva ends up at the position that “a patent ‘claims’ a product if the patent would be
infringed by the product.” (Id. at 15.) In support, Teva relies on the Second Circuit’s decision
in United Food. (Id.) The problem for Teva is that, as just stated, the Second Circuit in
United Food based its entire analysis on this fundamental principle: “patent claims ‘are the

numbered paragraphs which particularly point out and distinctly claim the subject matter which
the applicant regards as his invention.” (United, 11 F.4th at 132 (quoting Corning Glass Works
v. Sumitomo Elec. U.S.A., Inc., 868 F.2d 1251, 1258 (Fed. Cir. 1989)). Thus, a patent claims
only that subject matter that it has particularly pointed out as the invention, and no more. This
is inconsistent with Teva’s contention that a patent claims all products that are infringing.
Furthermore, the Second Circuit carefully explained the difference between the meaning of
“claims” in patent law and “infringement.” Id. at 134. In short, Teva has failed to persuade
that, applying the common meaning of “claims” in patent law, any claim in any of the Inhaler

14
Patents particularly identifies the subject of the NDA application, an albuterol sulfate HFA
Inhalation Aerosol, as the invention.
Second, Teva points to the broad statutory definition of “drug.” The Court agrees with
Teva that the statute, 21 U.S.C. § 321(g)(1), expressly gives the term, “drug,” a broad scope, and
specifically includes “articles intended for use as a component of any article” intended for use

for the treatment of disease. Given the broad statutory definition of “drug,” the Inhaler Patents
do claim articles intended for use as a component of the ProAir® HFA (albuterol sulfate)
Inhalation Aerosol, and it is undisputed that the albuterol sulfate HFA Inhalation Aerosol is
intended for the treatment of disease. The problem for Teva is that this determination does not
suffice to establish that the Inhaler Patents “claim[] the drug for which the applicant submitted
the application,” as required by the Listing Statute. Teva’s arguments overlook the statutory
phrase which modifies “drug:” “for which the applicant submitted the application.” The drug
for which the applicant submitted the application is “albuterol sulfate HFA Inhalation Aerosol.”
The Inhaler Patents do not contain any claims which claim “albuterol sulfate HFA Inhalation

Aerosol.” In short, the fact that the statutory definition of “drug” expressly includes devices for
treating disease, and their components, does not nullify the restrictive action of the modifying
phrase, “for which the applicant submitted the application.” Teva tries hard to get around the
effect of this modifying phrase, but fails to do so.
Lastly, as already noted, Teva maintains that the Inhaler Patents have been listed as “drug
product” patents, within the meaning of § 355. The relevant Regulation defines “drug product”
as follows: “Drug product is a finished dosage form, e.g., tablet, capsule, or solution, that
contains a drug substance, generally, but not necessarily, in association with one or more other

15
ingredients.” 21 C.F.R. § 314.3(b). As the FTC observes, the Regulations also state: “For
patents that claim a drug product, the applicant must submit information only on those patents
that claim the drug product, as is defined in § 314.3, that is described in the pending or approved
NDA.” 21 C.F.R. § 314.53(b)(1)(italics added). The Inhaler Patents do not claim the
“finished dosage form” that is the subject of NDA No. 021457.

Furthermore, the FTC cites a response to public comments made by the FDA during the
2003 rulemaking process for the Regulation, 21 C.F.R. § 314.53:
(Comment 3) Most comments agreed that patents claiming packaging should not
be submitted for listing. However, some comments stated that patents claiming
devices or containers that are “integral” to the drug product or require prior FDA
approval should be submitted and listed. These comments distinguished between
packaging and devices such as metered dose inhalers and transdermal patches,
which are drug delivery systems used and approved in combination with a drug.

(Response) We agree that patents claiming a package or container must not be
submitted. Such packaging and containers are distinct from the drug product and
thus fall outside of the requirements for patent submission. However, we have
clarified the rule to ensure that if the patent claims the drug product as defined in
§ 314.3, the patent must be submitted for listing.

Section 314.3 defines a “drug product” as “* * * a finished dosage form, for
example, tablet, capsule, or solution, that contains a drug substance, generally, but
not necessarily, in association with one or more other ingredients.” The appendix
in the Orange Book lists current dosage forms for approved drug products. The
list includes metered aerosols, capsules, metered sprays, gels, and pre-filled drug
delivery systems. The key factor is whether the patent being submitted claims the
finished dosage form of the approved drug product. Patents must not be submitted
for bottles or containers and other packaging, as these are not “dosage forms.”

68 Fed. Reg. 36676, 36680 (italics added). The Inhaler Patents do not claim the finished
dosage form of the approved drug product.
The Court concludes that the Inhaler Patents do not meet a key requirement of the Listing
Statute: they do not claim “the drug for which the applicant submitted the application,” NDA No.

16
021457, ProAir® HFA (albuterol sulfate) Inhalation Aerosol. Nor do the Inhaler Patents claim
the “finished dosage form” that is the subject of that NDA application. Because the Inhaler
Patents fail to meet these requirements, that have been improperly listed in the Orange Book.
As to Counterclaim Counts 1-5, Teva’s motion to dismiss will be denied. Amneal has
demonstrated that, on the basis of the pleadings, it is entitled to judgment as a matter of law on

Counterclaim Counts 1-5. Amneal’s motion for judgment on the pleadings will be granted.
For these reasons,
IT IS on this 10th day of June, 2024
ORDERED that Plaintiff’s motion to dismiss Counterclaim Counts 1-10 (Docket Entry
No. 26) is DENIED; and it is further
ORDERED that Defendant’s motion for partial judgment on the pleadings (Docket Entry
No. 41) is GRANTED; and it is further
ORDERED that Judgment is entered in Defendants’ favor as to Counts 1-5 of
Defendants’ Counterclaims; and it is further

ORDERED that it is the Judgment of this Court that U.S. Patent Nos. 8,132,712,
9,463,289, 9,808,587, 10,561,808, and 11,395,889 have been improperly listed in the Orange
Book in regard to the drug product that is the subject of NDA No. 021457; and it is further
ORDERED that, pursuant to 21 U.S.C. § 355(j)(5)(c)(ii)(I), Teva must correct or delete
the relevant Orange Book patent information listings to reflect the Judgment of this Court.

/s Stanley R. Chesler
STANLEY R. CHESLER. U.S.D.J.

17

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/cases/10278859. Public record. Not legal advice.